Equities
Health CarePharmaceuticals and Biotechnology
  • Price (CHF)6.09
  • Today's Change0.28 / 4.82%
  • Shares traded38.71k
  • 1 Year change+5.55%
  • Beta0.3357
Data delayed at least 15 minutes, as of Jul 05 2024 16:31 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Molecular Partners AG is a Switzerland-based clinical-stage biotech company developing DARPin (Designed Ankyrin Repeat Proteins) a new class of custom-built protein therapeutics based on natural binding proteins that open a new dimension of multi-functionality and multi-target specificity in drug design. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics , and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.

  • Revenue in CHF (TTM)6.73m
  • Net income in CHF-58.53m
  • Incorporated2004
  • Employees168.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Xlife Sciences AG988.44k14.88m168.82m17.0024.310.61736.67170.791.221.220.138247.950.002--0.204458,143.531.85--2.33--45.43--938.17------0.1345---3.85--3.96------
BioInvent International AB5.23m-28.60m182.86m109.00--1.74--34.97-5.08-5.080.92918.730.041--1.29550,927.90-22.41-17.50-23.68-18.64-----547.02-131.6313.34--0.0169---78.0913.14-677.13--28.17--
Vicore Pharma Holding AB8.91m-18.21m183.43m26.00--4.39--20.58-2.15-2.151.014.380.2589--14.414,343,459.00-52.89-58.65-59.34-65.58-----204.27------0.00-------7.81------
Genfit SA37.08m-28.06m185.40m159.00--2.81--5.00-0.5814-0.58140.76811.360.1961542.003.52240,100.60-14.84-12.57-18.55-15.3094.3294.96-75.69-76.232.94-7.780.5080--43.7038.49-21.82---3.27--
XSpray Pharma AB (publ)0.00-18.18m188.79m26.00--4.01-----7.66-7.660.0020.000.00----0.00-33.92-18.38-36.11-19.26--------2.24--0.0536-------36.45--2.87--
Sensorion SA0.00-21.43m199.05m50.00--3.83-----0.2063-0.20630.000.17790.00-------51.64-35.12-71.66-46.97------------0.0794------4.94--126.45--
hVIVO PLC64.34m18.50m216.35m274.0011.845.4910.013.360.02340.02340.08170.05050.8327--4.08204,536.5023.94-0.64346.27-1.29----28.75-0.7651.47--0.2674--15.6135.402,176.68--136.55--
Molecular Partners AG6.73m-58.53m223.40m168.00--1.19--33.21-1.78-1.780.20435.13------40,035.71---11.83---14.69--99.28-870.22-45.30----0.0195---96.29-7.43-152.59---1.40--
Nanobiotix SA29.19m-38.56m223.40m102.00------7.65-1.10-1.100.814-0.03910.3912--19.59294,686.30-51.67-54.11-120.56-80.68-----132.08-756.15---1.981.04----203.8830.40---7.81--
4Basebio PLC580.87k-8.80m230.05m--------396.05-0.6222-0.62220.0411-0.03990.04290.7146.29---64.93---77.36--67.19---1,514.82--2.06-26.661.05--88.81---48.83------
Ryvu Therapeutics SA12.61m-21.30m259.51m230.00--5.86--20.58-4.10-4.102.428.450.130212.394.99241,760.90-21.99-21.88-24.87-25.2056.80-6.28-168.89-284.204.71--0.1193--20.32-9.50-9.94--53.71--
Allergy Therapeutics plc61.14m-57.65m259.91m635.00--8.56--4.25-0.0266-0.02660.0170.00560.75712.214.9283,870.87-71.39-11.59-102.10-15.1552.5470.08-94.29-11.780.9281-7.930.2713---18.11-2.71-212.65--16.41--
Bioventix PLC15.61m9.95m265.15m16.0027.1120.2026.2816.991.631.632.562.191.091.532.54849,780.6069.7256.4379.0361.0193.7592.6463.7365.086.69--0.0084.499.367.939.108.13-37.1220.03
Avacta Group Plc26.69m-28.64m279.45m154.00------10.47-0.0914-0.09140.0853--------150,954.50--------48.37---107.31-----0.575----140.83--32.54------
Hansa Biopharma AB14.18m-72.24m280.99m166.00------19.81-16.07-16.073.15-7.100.142464.031.86987,386.90-72.51-47.96-92.27-56.1256.8064.18-509.33-835.042.55-9.651.65---13.22109.06-36.09---35.24--
Selvita SA76.47m14.81m283.03m387.0019.123.8111.073.703.563.5618.3717.830.5539.294.70398,178.3010.71--12.99--79.66--19.36--1.4111.340.4063---3.48--130.55------
Data as of Jul 05 2024. Currency figures normalised to Molecular Partners AG's reporting currency: Swiss Franc CHF

Institutional shareholders

41.44%Per cent of shares held by top holders
HolderShares% Held
BVF Partners LPas of 17 Nov 20238.70m23.71%
Suvretta Capital Management LLCas of 31 Dec 20231.75m4.77%
UBS Asset Management Switzerland AGas of 04 Jun 20241.13m3.08%
EcoR1 Capital, LLCas of 17 Nov 20231.09m2.96%
GAM Investment Management (Switzerland) AGas of 21 Nov 20221.07m2.91%
Credit Suisse Asset Management (Schweiz) AGas of 29 Mar 2024483.42k1.32%
Union Bancaire Priv�e, UBP SAas of 31 Mar 2024411.50k1.12%
Z�rcher Kantonalbank (Investment Management)as of 31 May 2024292.49k0.80%
ACATIS Investment Kapitalverwaltungsgesellschaft mbHas of 30 Apr 2024200.06k0.55%
Pictet Asset Management SAas of 31 Mar 202483.92k0.23%
More ▼
Data from 31 Mar 2024 - 28 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.